The conversion was at 12 per cent premium to the market price. NYLIM Jacob Ballas Fund III, managed by Jacob Ballas Capital India Pvt Ltd, has... ...
http://www.vccircle.com/news/pharmaceuticals/2013/03/22/jacob-ballas-picks-131-stake-vivimed-labs-conversion-preference